trending Market Intelligence /marketintelligence/en/news-insights/trending/dMC08jcTb_WMBn8RB3uEOQ2 content esgSubNav
In This List

Innate Pharma blood cancer drug accepted for EU review

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Innate Pharma blood cancer drug accepted for EU review

Innate Pharma SA said the European Medicines Agency accepted its application seeking approval for its blood cancer treatment Lumoxiti.

The Marseille, France-based drugmaker is seeking approval for Lumoxiti to treat adults with hairy cell leukemia who have received at least two prior systemic therapies — including a purine nucleoside analog — but whose disease returned or did not respond to existing treatment.

Hairy cell leukemia is a rare, chronic and slow-growing leukemia in which the bone marrow overproduces abnormal B cell lymphocytes, a type of white blood cell.

The filing is based on the results of a late stage trial of Lumoxiti, or moxetumomab pasudotox-tdfk, which showed the medicine benefited patients. Innate licensed Lumoxiti from AstraZeneca PLC in October 2018.

The U.S. Food and Drug Administration approved Lumoxiti in September 2018 under its priority review process.